Eli Lilly (LLY23) Stock Overview
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
LLY23 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Eli Lilly and Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.72 |
| 52 Week High | US$4.28 |
| 52 Week Low | US$3.60 |
| Beta | 0.50 |
| 1 Month Change | -9.27% |
| 3 Month Change | -4.12% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -4.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| LLY23 | TH Pharmaceuticals | TH Market | |
|---|---|---|---|
| 7D | -3.1% | -3.0% | 2.4% |
| 1Y | n/a | -9.0% | 25.0% |
Return vs Industry: Insufficient data to determine how LLY23 performed against the TH Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how LLY23 performed against the TH Market.
Price Volatility
| LLY23 volatility | |
|---|---|
| LLY23 Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in TH Market | 9.2% |
| 10% least volatile stocks in TH Market | 2.0% |
Stable Share Price: LLY23 has not had significant price volatility in the past 3 months compared to the TH market.
Volatility Over Time: Insufficient data to determine LLY23's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1876 | 50,000 | Dave Ricks | www.lilly.com |
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin’s lymphoma; and Verzenio for breast cancer.
Eli Lilly and Company Fundamentals Summary
| LLY23 fundamental statistics | |
|---|---|
| Market cap | ฿33.08t |
| Earnings (TTM) | ฿882.75b |
| Revenue (TTM) | ฿2.63t |
Is LLY23 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LLY23 income statement (TTM) | |
|---|---|
| Revenue | US$79.67b |
| Cost of Revenue | US$13.23b |
| Gross Profit | US$66.44b |
| Other Expenses | US$39.73b |
| Earnings | US$26.71b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
Oct 29, 2026
| Earnings per share (EPS) | 29.97 |
| Gross Margin | 83.40% |
| Net Profit Margin | 33.53% |
| Debt/Equity Ratio | 162.1% |
How did LLY23 perform over the long term?
See historical performance and comparisonDividends
Does LLY23 pay a reliable dividends?
See LLY23 dividend history and benchmarks| Eli Lilly dividend dates | |
|---|---|
| Ex Dividend Date | Aug 14 2026 |
| Dividend Pay Date | Oct 05 2026 |
| Days until Ex dividend | 29 days |
| Days until Dividend pay date | 23 days |
Does LLY23 pay a reliable dividends?
See LLY23 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/11 23:58 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eli Lilly and Company is covered by 53 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Kerry Holford | Berenberg |